Abstract
The physiologic sequelae of Renal Artery Stenosis (RAS) results from narrowing of renal artery lumen which leads to diminished renal perfusion. The consequences of RAS range from asymptomatic to refractory hypertension to ischemic nephropathy eventually leading to end-stage renal disease (ESRD).
Keywords: Renal Artery Stenosis (RAS), hypertension, end-stage renal disease (ESRD), nephropathy, etiology
Current Hypertension Reviews
Title: Renal Artery Stenting: Efficacy and Complications
Volume: 5 Issue: 1
Author(s): Mohsen Bannazadeh and Timur Sarac
Affiliation:
Keywords: Renal Artery Stenosis (RAS), hypertension, end-stage renal disease (ESRD), nephropathy, etiology
Abstract: The physiologic sequelae of Renal Artery Stenosis (RAS) results from narrowing of renal artery lumen which leads to diminished renal perfusion. The consequences of RAS range from asymptomatic to refractory hypertension to ischemic nephropathy eventually leading to end-stage renal disease (ESRD).
Export Options
About this article
Cite this article as:
Bannazadeh Mohsen and Sarac Timur, Renal Artery Stenting: Efficacy and Complications, Current Hypertension Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157340209787314342
DOI https://dx.doi.org/10.2174/157340209787314342 |
Print ISSN 1573-4021 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6506 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers
Current Drug Targets Indazole Derivatives: Promising Anti-tumor Agents
Anti-Cancer Agents in Medicinal Chemistry Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Subpopulations of Bone Marrow Mesenchymal Stem Cells Exhibit Differential Effects in Delaying Retinal Degeneration
Current Molecular Medicine Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Triglycerides and Cardiovascular Risk
Current Cardiology Reviews Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs
Current Pharmaceutical Design Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Brain Angiotensin and Cardiovascular Reactivity to Negative and Positive Emotional Stress
Current Hypertension Reviews Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) Pathophysiological Implications of Dipeptidyl Peptidases
Current Protein & Peptide Science Statins: Are They All the Same?
Current Drug Therapy Chemistry and Biological Activities of Caffeic Acid Derivatives from Salvia miltiorrhiza
Current Medicinal Chemistry Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiac Consequences of Anti-Inflammatory Drugs in Experimental Models
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Can Targeted Therapy be Successful without Metronomic Scheduling ?
Current Topics in Medicinal Chemistry Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma
Current Drug Targets